Tag: Illegal activities in pharma
Trump’s Anti-Bribery Law Pause: Impact on Pharma Behavior
Between 2011 and 2020, the world witnessed a staggering $1.34 billion in fines paid by the top pharmaceutical companies to the U.S. government for...
BREAKING NEWS
Reforming FDA Advisory Committee Policy for Conflict of Interest-Free Decisions
Peter J. Pitts, a distinguished figure in the realm of healthcare regulation, recently shared his insights on the critical issue of FDA Advisory Committee...
